On Tuesday, Medtronic Plc (NYSE:MDT) reported second-quarter earnings and announced key board appointments after Elliott Investment Management became the company’s largest shareholder.
The company also unveiled its new Growth Committee, tasked with overseeing the evaluation and execution of strategic M&A, R&D investments, and potential divestitures, including the planned separation of its Diabetes business.
Medtronic reported first-quarter 2026 results, with sales hitting $8.58 billion, surpassing the consensus estimate of $8.38 billion. This marks an 8.4% increase year-over-year, with organic growth of 4.8%. Adjusted earnings of $1.26 per share also beat expectations of $1.23.
Also Read: Medtronic Stock …